IL6 and prostate cancer: In prostate cancer, LNCaP and 22Rv1 prostate cancer cells transiently overexpress androgen receptor splice variant-7 (AR-V7), and consequently activate the nuclear factor-kappa B (NF-κB) and upregulate interleukin (IL)-6 gene expression.